A randomized, double-blind, placebo and reference controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of Memogain administered by intranasal application to healthy elderly subjects.

Trial Profile

A randomized, double-blind, placebo and reference controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of Memogain administered by intranasal application to healthy elderly subjects.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2018

At a glance

  • Drugs GLN 1062 (Primary) ; Galantamine
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Neurodyn
  • Most Recent Events

    • 24 Mar 2018 Status changed to active, no longer recruiting.
    • 24 Mar 2018 Primary endpoint (Adaptive tracking performance (22 mg GLN-1062 vs Placebo)) has been met as per the results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 24 Mar 2018 Primary endpoint (Reaction time on the n-back test (22 mg GLN-1062 vs Placebo)) has been met as per the results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top